0 334

Cited 0 times in

Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study

DC Field Value Language
dc.contributor.author유영훈-
dc.contributor.author조응혁-
dc.date.accessioned2021-05-21T17:09:49Z-
dc.date.available2021-05-21T17:09:49Z-
dc.date.issued2020-03-
dc.identifier.issn1619-7070-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182738-
dc.description.abstractPurpose: We investigated whether predictive clinicopathologic factors can be affected by different response criteria and how the clinical usefulness of radioactive iodine (RAI) therapy should be evaluated considering variable factors in patients with differentiated thyroid carcinoma (DTC). Methods: A total of 1563 patients with DTC who underwent first RAI therapy after total or near total thyroidectomy were retrospectively enrolled from 25 hospitals. Response to therapy was evaluated with two different protocols based on combination of biochemical and imaging studies: (1) serum thyroglobulin (Tg) and neck ultrasonography (US) and (2) serum Tg, neck US, and radioiodine scan. The responses to therapy were classified into excellent and non-excellent or acceptable and non-acceptable to minimize the effect of non-specific imaging findings. We investigated which factors were associated with response to therapy depending on the follow-up protocols as well as response classifications. Multivariate logistic regression analysis was performed to identify factors significantly predicting response to therapy. Results: The proportion of patients in the excellent response group significantly decreased from 76.5 to 59.6% when radioiodine scan was added to the follow-up protocol (P < 0.001). Preparation method (recombinant human TSH vs. thyroid hormone withdrawal) was a significant factor for excellent response prediction evaluated with radioiodine scan (OR 2.129; 95% CI 1.687-2.685; P < 0.001) but was not for other types of response classifications. Administered RAI activity, which was classified as low (1.11 GBq) or high (3.7 GBq or higher), significantly predicted both excellent and acceptable responses regardless of the follow-up protocol. Conclusions: The clinical impact of factors related to response prediction differed depending on the follow-up protocol or classification of response criteria. A high administered activity of RAI was a significant factor predicting a favorable response to therapy regardless of the follow-up protocol or classification of response criteria.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-Verlag Berlin-
dc.relation.isPartOfEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleClinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Nuclear Medicine (핵의학교실)-
dc.contributor.googleauthorSeong Young Kwon-
dc.contributor.googleauthorSang-Woo Lee-
dc.contributor.googleauthorEun Jung Kong-
dc.contributor.googleauthorKeunyoung Kim-
dc.contributor.googleauthorByung Il Kim-
dc.contributor.googleauthorJahae Kim-
dc.contributor.googleauthorHeeyoung Kim-
dc.contributor.googleauthorSeol Hoon Park-
dc.contributor.googleauthorJisun Park-
dc.contributor.googleauthorHye Lim Park-
dc.contributor.googleauthorSo Won Oh-
dc.contributor.googleauthorKyoung Sook Won-
dc.contributor.googleauthorYoung Hoon Ryu-
dc.contributor.googleauthorJoon-Kee Yoon-
dc.contributor.googleauthorSoo Jin Lee-
dc.contributor.googleauthorJong Jin Lee-
dc.contributor.googleauthorAri Chong-
dc.contributor.googleauthorYoung Jin Jeong-
dc.contributor.googleauthorJu Hye Jeong-
dc.contributor.googleauthorYoung Seok Cho-
dc.contributor.googleauthorArthur Cho-
dc.contributor.googleauthorGi Jeong Cheon-
dc.contributor.googleauthorEun Kyoung Choi-
dc.contributor.googleauthorJae Pil Hwang-
dc.contributor.googleauthorSang Kyun Bae-
dc.identifier.doi10.1007/s00259-019-04634-8-
dc.contributor.localIdA02485-
dc.contributor.localIdA03887-
dc.relation.journalcodeJ00833-
dc.identifier.eissn1619-7089-
dc.identifier.pmid31820047-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00259-019-04634-8-
dc.subject.keywordDifferentiated thyroid carcinoma-
dc.subject.keywordRadioactive iodine therapy-
dc.subject.keywordRecombinant human thyrotropin-
dc.subject.keywordResponse to therapy-
dc.contributor.alternativeNameRyu, Young Hoon-
dc.contributor.affiliatedAuthor유영훈-
dc.contributor.affiliatedAuthor조응혁-
dc.citation.volume47-
dc.citation.number3-
dc.citation.startPage561-
dc.citation.endPage571-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.47(3) : 561-571, 2020-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.